Research programme: lung cancer therapeutics - ProMIS Neurosciences/MD Anderson Cancer Center

Drug Profile

Research programme: lung cancer therapeutics - ProMIS Neurosciences/MD Anderson Cancer Center

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Amorfix Life Sciences; University of Texas M. D. Anderson Cancer Center
  • Developer ProMIS Neurosciences; University of Texas M. D. Anderson Cancer Center
  • Class Antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Lung cancer

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for research development in Lung-cancer in USA (Parenteral)
  • 14 Jul 2015 ProMIS Neurosciences is now called Amorfix Life Sciences
  • 25 Apr 2013 Early research in Lung cancer in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top